Traditionally viewed as simply the opposite of insulin, a hormone that raises blood sugar, glucagon was avoided in metabolic therapies
No serious adverse effects were reported across the trials
In the landmark Phase 3 VESALIUS-CV trial (12,000+ patients), adding Repatha to standard cholesterol-lowering therapy significantly reduced the risk of: Heart attacks Ischemic strokes Coronary deaths This makes Repatha the first PCSK9 inhibitor to demonstrate preventive benefits before heart disease strikes a true paradigm shift in cardiovascular care
Department of Education Higher Education Emergency Relief Fund
Similar to medications for chronic conditions, like asthma, diabetes or high blood pressure, GLP-1 medications only work for those who continue to take them
Long-acting glucagon-like peptide-1 receptor agonists have direct access to and effects on pro-opiomelanocortin/cocaine- and amphetamine-stimulated transcript neurons in the mouse hypothalamus